Table 1.
Baseline Characteristics of Patients in GOLD B, Split into GOLD B0 and B1
| GOLD B0 | GOLD B1 | P-value | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Patients | 4,545 | 3,908 | |||
| Sex | |||||
| Male | 2,323 | 51.1 | 1,951 | 49.9 | 0.276 |
| Female | 2,222 | 48.9 | 1,957 | 50.1 | |
| Cohabitation status | |||||
| Not cohabitating | 2,398 | 52.8 | 1,918 | 49.1 | <0.001 |
| Cohabitating | 2,147 | 47.2 | 1,990 | 50.9 | |
| Age (years) | |||||
| Mean age (SD) | 70.1 (10.2) | 69.9 (10.2) | 0.430 | ||
| 40–49 | 152 | 3.3 | 122 | 3.1 | 0.712 |
| 50–59 | 599 | 13.2 | 551 | 14.1 | |
| 60–69 | 1,264 | 27.8 | 1,100 | 28.1 | |
| 70–79 | 1,683 | 37.0 | 1,423 | 36.4 | |
| 80+ | 847 | 18.6 | 712 | 18.2 | |
| mMRC score | |||||
| 2 | 2,556 | 56.2 | 2,143 | 54.8 | 0.422 |
| 3 | 1,347 | 29.6 | 1,189 | 30.4 | |
| 4 | 642 | 14.1 | 576 | 14.7 | |
| FEV1 (% of predicted) | |||||
| 80+ | 185 | 4.1 | 127 | 3.2 | 0.114 |
| 50–79 | 1,722 | 37.9 | 1,436 | 36.7 | |
| 30–49 | 1,904 | 41.9 | 1,691 | 43.3 | |
| <30 | 734 | 16.1 | 654 | 16.7 | |
| BMI (kg/m2) | |||||
| <18 | 458 | 10.1 | 380 | 9.7 | 0.879 |
| 18–24 | 1,609 | 35.4 | 1,373 | 35.1 | |
| 25–29 | 1,328 | 29.2 | 1,129 | 28.9 | |
| 30–34 | 728 | 16.0 | 644 | 16.5 | |
| 35+ | 422 | 9.3 | 382 | 9.8 | |
| Smoking status | |||||
| Not current smoker | 2,903 | 63.9 | 2,519 | 64.5 | 0.576 |
| Current smoker | 1,642 | 36.1 | 1,389 | 35.5 | |
| Baseline treatment* | |||||
| No claims | 1,376 | 30.3 | 966 | 24.7 | <0.001 |
| LAMA | 561 | 12.3 | 440 | 11.3 | |
| LABA | 163 | 3.6 | 150 | 3.8 | |
| LABA/ICS | 727 | 16.0 | 709 | 18.1 | |
| LABA/LAMA | 211 | 4.6 | 193 | 4.9 | |
| LABA/LAMA/ICS | 1,507 | 33.2 | 1,450 | 37.1 | |
| Charlson Comorbidity Index (CCI) | |||||
| Mean (SD) | 0.36 (0.89) | 0.36 (0.88) | 0.7190 | ||
Note: *Medication claimed 4 months prior to index.
Abbreviations: SD, standard deviation; mMRC, modified Medical Research Council; FEV1, forced expired volume in the first second; BMI, body mass index; LAMA, long-acting muscarinic antagonists; LABA, long-acting beta-agonists; ICS, inhaled corticosteroids.